Entera Bio Ltd.
ENTX
Rank in Stocks
#11430
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase,... Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Share Price
$3.25
Last synced: 2026-11-09
Market Cap
$565.25M
Change (1 day)
3.50%
Change (1 year)
7.97%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Entera Bio Ltd. (ENTX)
Category
Healthcare
Operating Margin for Entera Bio Ltd. (ENTX)
Operating Margin as of November 2026 TTM: 0.00%
According to Entera Bio Ltd.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of -27,450.00%.
Operating Margin history for Entera Bio Ltd. from 2015 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | -27,450.00% | 418.36% |
| 2024 | -5,295.58% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -9,752.24% | 355.80% |
| 2021 | -2,139.58% | -30.07% |
| 2020 | -3,059.73% | -36.96% |
| 2019 | -4,853.39% | 123.43% |
| 2018 | -2,172.20% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Entera Bio Ltd.'s operating margin
What was Entera Bio Ltd.'s operating margin in 2025?
In 2025, Entera Bio Ltd.'s operating margin was -27,450.00%, compared with -5,295.58% in 2024.
How has Entera Bio Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Entera Bio Ltd.'s operating margin was highest in 2023 (0.00%) and lowest in 2025 (-27,450.00%).
How does Entera Bio Ltd.'s operating margin compare with similar companies?
Entera Bio Ltd.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.